Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 5/20 | 0.57 |
| ▸ | AMPD2 | Q01433 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | XIAP | P98170 | 5/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CCKBR | P32239 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.41 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.41 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4422374 | 1.00 | BRD4 (0.57) | BRD4AMPD2MEN1KMT2APOLB | |
| SCHEMBL4436008 | 0.90 | BRD4 (0.47) | BRD4AMPD2MEN1KMT2APOLB | |
| SCHEMBL4425596 | 0.85 | NOTUM (0.46) | BRD4AMPD2POLBXIAPNOTUM | |
| SCHEMBL4425590 | 0.85 | NOTUM (0.46) | BRD4AMPD2POLBXIAPNOTUM | |
| SCHEMBL13893623 | 0.84 | BRD4 (0.56) | BRD4AMPD2MEN1KMT2APOLB | |
| SCHEMBL14599959 | 0.82 | BRD4 (0.55) | BRD4AMPD2MEN1KMT2APOLB | |
| SCHEMBL4434152 | 0.81 | NOTUM (0.42) | BRD4POLBXIAPNOTUM | |
| Hydrochloric Acid SCHEMBL4429072 | 0.80 | NOTUM (0.41) | BRD4POLBXIAPCYP3A4NOTUM | |
| Hydrochloric Acid SCHEMBL4429066 | 0.80 | NOTUM (0.41) | BRD4POLBXIAPCYP3A4NOTUM | |
| Hydrochloric Acid SCHEMBL4426338 | 0.77 | NOTUM (0.48) | BRD4POLBNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1711470-B1 | MALONAMIDE DERIVATIVES BLOCKING THE ACTIVTIY OF GAMMA-SECRETASE | HOFFMANN LA ROCHE (CH) | 2009-04-15 | — | — | EP | disclosed |
| US-7160875-B2 | Malonamide derivatives | HOFFMANN-LA RACHE INC. (US) | 2007-01-09 | — | — | US | disclosed |
| EP-1711470-A1 | MALONAMIDE DERIVATIVES BLOCKING THE ACTIVTIY OF GAMMA-SECRETASE | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005023772-A1 | MALONAMIDE DERIVATIVES BLOCKING THE ACTIVITY OF GAMA-SECRETASE | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-17 | — | — | WO | disclosed |
| US-20050054633-A1 | secretase inhibitors; therapy for Alzheimer's disease | HOFFMANN-LA ROCHE INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054633-A1 | secretase inhibitors; therapy for Alzheimer's disease | BACE1, BACE2, APP | BRD4 3002/4885AMPD2 3220/4885MEN1 1679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.